Oncology

The updated version of the Oncology Care Model (OCM) incentivizes value-based care over volume, but some wonder if it is enough.

Kimberly Westrich, MA, discussed value assessment tools and how they can help make key decisions in health care spending.

Pembrolizumab (Keytruda) gains its sixth approval in non–small cell lung cancer (NSCLC), with the latest indication in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a monotherapy for the post-surgical adjuvant treatment of patients with resectable NSCLC.

Mental health treatment may be necessary when SAEs occur.

In clinical trials, nivolumab (Opdivo) demonstrated a statistically significant improvement in recurrence-free survival compared to placebo in eligible patients with stages IIB, IIC, III, and stage IV completely resected melanoma.

AI systems can detect minute anomalies often missed by the human eye, reducing false negatives.

Trial data bolster the role of nivolumab and nivolumab-based combinations in both early and metastatic stages of multiple cancer types, especially in patient groups with high unmet needs.

TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of the EGFR signaling pathway.

Karline Peal, MBA of Vanderbilt Ingram Cancer Center discusses the positive impact technology has had in health care and how it can be implemented in the future.

The president of HOPA discusses the importance of mentorship in oncology pharmacy as well as the value of HOPA’s mentorship initiatives.

Encorafenib (Braftovi; Pfizer Inc) and binimetinib (Mektovi; Pfizer Inc) approved for the treatment of patients with metastatic non-small cell lung cancer who harbor a BRAF V600E mutation.

Collaboration between AI-based platforms and health care organizations offers promising results.

The clinical trial success in canines may have broader implications for applicability.

A single-center experience at a tertiary medical center precision medicine clinic provides insight.

Within this care model, pharmacists can serve an important role in caring for patients, whether it is identifying adverse medication interactions or pushing patients to seek additional support.

Providing clinical trials at community locations allows patients with travel restrictions to access novel treatments that are typically studied academic institutions.

Not only did the Navya-Patient Preference Tool help patients with decision-making, but groups who used the tool were more likely to receive their preferred form of surgery.

Little progress has been made in developing treatments that can help to stop Ewing sarcomas from spreading or coming back.

Oncolytic polymers may be the answer to circumventing therapeutic resistance in cancer treatment.

The results also indicate an association with increased risk of colorectal and noncolorectal gastrointestinal cancers as body mass index increases over time.

Up to 81% of patients with cancer take medications to treat their other comorbidities.

The manager of patient support services at St. Luke’s Cancer Center discusses the significance of Reaching Out for Healthy Women and how female patients can receive support from this initiative.

Lack of awareness, cultural beliefs, and physician preferences may influence whether minority patients receive palliative care during metastatic breast cancer treatment.

Diversity in patient populations, including age, race, ethnicity, and underrepresented regions, have increased in early-phase National Cancer Institute-sponsored trials.

Intravenous immunoglobulin could potentially be given throughout the duration of anti-BCMA bispecific antibody therapy for the treatment of multiple myeloma.

Cancer mortality rates increased by 3.3 deaths per 100,000 individuals and was higher for historically minoritized populations.

Ongoing studies utilizing large-scale health databases that incorporate environmental, lifestyle, biological, and phenotypic data may provide insight that leads to better cancer prevention and treatment.

Artificial intelligence has helped ensure a data-driven methodology for evaluating eligibility criteria for clinical trials, facilitating more inclusive trial design.